1. |
Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail, 2005, 11(5): S76-S80.
|
2. |
Wieshammer S, Dreyhaupt J, Basler B, et al. NT-proBNP for pulmonologists: not only a rule-out test for systolic heart failure but also a global marker of heart disease. Respiration, 2009, 77(4): 370-380.
|
3. |
Bower JK, Lazo M, Matsushita K, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the atherosclerosis risk in communities (ARIC) study. Am J Hypertens, 2015, 28(10): 1262-1266.
|
4. |
Lee SM, Kwon JE, Song SH, et al. Prenatal prediction of neonatal death in single ventricle congenital heart disease. Prenat Diagn, 2016, 36(4): 346-352.
|
5. |
Norozi K, Buchhorn R, Kaiser C, et al. Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest, 2005, 128(4): 2563-2570.
|
6. |
Plymen CM, Hughes ML, Picaut N, et al. The relationship of systemic right ventricular function to ECG parameters and NT-proBNP levels in adults with transposition of the great arteries late after Senning or Mustard surgery. Heart, 2010, 96(19): 1569-1573.
|
7. |
Popelová J, Kotaška K, Černý S, et al. Range and distribution of NT-proBNP values in stable corrected congenital heart disease of various types. Can J Cardiol, 2012, 28(4): 471-476.
|
8. |
Langley SM, Sunstrom RE, Reed RD, et al. The neonatal hypoplastic aortic arch: decisions and more decisions. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, 2013, 16(1): 43-51.
|
9. |
Jenkins KJ, Gauvreau K, Newburger JW, et al. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg, 2002, 123(1): 110-118.
|
10. |
Albers S, Mir TS, Haddad M, et al. N-terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med, 2006, 44(1): 80-85.
|
11. |
Kaushal S, Backer CL, Patel JN, et al. Coarctation of the aorta: midterm outcomes of resection with extended end-to-end anastomosis. Ann Thorac Surg, 2009, 88(6): 1932-1938.
|
12. |
Pérez-Piaya M, Abarca E, Soler V, et al. Levels of N-terminal-pro-brain natriuretic peptide in congenital heart disease surgery and its value as a predictive biomarker. Interact Cardiovasc Thorac Surg, 2011, 12(3): 461-466.
|
13. |
Koch AM, Rauh M, Zink S, et al. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr, 2006, 95(7): 805-809.
|
14. |
Heck PB, Müller J, Weber R, et al. Value of N-terminal pro brain natriuretic peptide levels in different types of Fontan circulation. Eur J Heart Fail, 2013, 15(6): 644-649.
|
15. |
Schou M, Gustafsson F, Corell P, et al. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J, 2007, 154(1): 123-129.
|
16. |
Windhausen F, Hirsch A, Sanders GT, et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST elevation acute coronary syndrome and an elevated troponin T: an invasive versus conservative treatment in unstable coronary syndromes (ICTUS) substudy. Am Heart J, 2007, 153(4): 485-492.
|
17. |
Berghaus TM, Kutsch J, Faul C, et al. The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study. BMC Pulm Med, 2017, 17(1): 167.
|